7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

返回 Agenda

[Session 6] Strategies to Assess, Prevent and Mitigate Cardiotoxicity

Session Chair(s)

Yuji Kumagai, MD, PHD

Professor, Kitasato Clinical Research Center, Kitasato University Hospital, Japan

Boaz Mendzelevski, MD

Consultant Cardiologist, Cardiac Safety Consultants Ltd., United Kingdom

Speaker(s)

Boaz Mendzelevski, MD

Consultant Cardiologist, Cardiac Safety Consultants Ltd., United Kingdom

Cardiovascular Safety Assessments of Oncology Drugs in Clinical Development

Manabu Minaimi, MD, PHD

Institute for Advancement of Clinical and Translational Science (iACT) , Kyoto University Hospital, Japan

Important Adverse Effects of Molecular-Targeting Drugs in Aspects of Cardio-Oncology

Wataru Shioyama, MD, PHD

Deputy Manager, Department of Cardiovascular Medicine, Onco-Cardiology Unit, Osaka International Cancer Institute, Japan

TKI Induced Cardiotoxicity and Drug-Induced Thrombosis

Krishna Prasad, DrMed, MD, MRCP, FRCP

Deputy Director, Innovative Medicines, HQA/Licensing, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Oncology Drug-Induced Cardiotoxicity: Strategies to Assess, Prevent and Mitigate Cardiotoxicity Pre- and Post-Approval

Hitoshi Kanno, MD, PHD

Reviewer, Office of New Drug V, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Cardio-Oncology from the Regulator’s Perspective

7th DIA Cardiac Safety Workshop in Japan

[Session 6] Strategies to Assess, Prevent and Mitigate Cardiotoxicity

Session Chair(s)

Yuji Kumagai, MD, PHD

Boaz Mendzelevski, MD

Speaker(s)

Boaz Mendzelevski, MD

Manabu Minaimi, MD, PHD

Wataru Shioyama, MD, PHD

Krishna Prasad, DrMed, MD, MRCP, FRCP

Hitoshi Kanno, MD, PHD

获得信息并保持参与